Skip to main content

Novanta Posts Solid 2025 Results With Strong Q4 Adjusted Earnings

Tipranks - Wed Feb 25, 4:36AM CST

Claim 50% Off TipRanks Premium

An update from Novanta ( (NOVT) ) is now available.

Novanta reported solid fourth-quarter and full-year 2025 results, with fourth-quarter GAAP revenue rising 9% to $258.3 million and a return to positive organic growth, even as GAAP operating income and diluted EPS were essentially flat year-on-year. Adjusted metrics were notably stronger, with fourth-quarter adjusted diluted EPS up 20% to $0.91 and adjusted EBITDA up 17% to $60.7 million, while for the full year revenue grew 3% to $980.6 million and adjusted EBITDA climbed to $221 million, underscoring resilient demand from medical and advanced technology customers despite some margin pressure on a GAAP basis.

The most recent analyst rating on (NOVT) stock is a Hold with a $155.00 price target. To see the full list of analyst forecasts on Novanta stock, see the NOVT Stock Forecast page.

Spark’s Take on NOVT Stock

According to Spark, TipRanks’ AI Analyst, NOVT is a Neutral.

The score is held back primarily by weakened cash flow and margin pressure despite strong longer-term revenue growth and an improved balance sheet. Technicals are supportive with the stock trading above key moving averages, and the earnings call outlook is constructive (bookings/design wins and 2026 growth guidance). However, the very high P/E elevates valuation risk and limits the overall score.

To see Spark’s full report on NOVT stock, click here.

More about Novanta

Novanta Inc., based in Bedford, Massachusetts, is a U.S.-listed technology company that serves as a key partner to medical and advanced technology equipment manufacturers. The group focuses on precision photonics, vision and motion technologies that are embedded in healthcare, industrial and scientific systems, positioning it in high-value, innovation-driven end markets.

Average Trading Volume: 447,824

Technical Sentiment Signal: Buy

Current Market Cap: $5.21B

For an in-depth examination of NOVT stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.